Kalaris Therapeutics, Inc. (KLRS) - Total Assets
Based on the latest financial reports, Kalaris Therapeutics, Inc. (KLRS) holds total assets worth $109.81 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check KLRS total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Kalaris Therapeutics, Inc. - Total Assets Trend (2018–2025)
This chart illustrates how Kalaris Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data. Explore Kalaris Therapeutics, Inc. (KLRS) investment intensity to see how much of total assets are deployed in long-term investments.
Kalaris Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Kalaris Therapeutics, Inc.'s total assets of $109.81 Million consist of 97.6% current assets and 2.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 80.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Kalaris Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see KLRS company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kalaris Therapeutics, Inc.'s current assets represent 97.6% of total assets in 2025, a decrease from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 80.6% of total assets in 2025, down from 98.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Kalaris Therapeutics, Inc. Competitors by Total Assets
Key competitors of Kalaris Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Kalaris Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.14 | 14.31 | 15.26 |
| Quick Ratio | 12.14 | 14.31 | 15.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $90.00 Million | $95.04 Million | $295.34 Million |
Kalaris Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Kalaris Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.51 |
| Latest Market Cap to Assets Ratio | 0.85 |
| Asset Growth Rate (YoY) | 2.7% |
| Total Assets | $121.74 Million |
| Market Capitalization | $103.73 Million USD |
Valuation Analysis
Near Book Valuation: The market values Kalaris Therapeutics, Inc.'s assets close to their book value (0.85x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: Kalaris Therapeutics, Inc.'s assets grew by 2.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Kalaris Therapeutics, Inc. (2018–2025)
The table below shows the annual total assets of Kalaris Therapeutics, Inc. from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $121.74 Million | +2.69% |
| 2024-12-31 | $118.55 Million | +3456.74% |
| 2023-12-31 | $3.33 Million | -14.52% |
| 2022-12-31 | $3.90 Million | -98.64% |
| 2021-12-31 | $286.59 Million | -22.71% |
| 2020-12-31 | $370.82 Million | +165.97% |
| 2019-12-31 | $139.42 Million | +450.66% |
| 2018-12-31 | $25.32 Million | -- |
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudativ… Read more